Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-11 | New | $175,000 | $175,000 | Debt Only | 06b | SEC link |
| 2021-11-01 | New | $596,013 | $596,013 | Equity Only | 06b | SEC link |
| 2020-08-28 | New | $398,715 | $398,715 | Equity Only | 06b | SEC link |
| 2020-02-05 | Amended | $5,302,550 | $1,332,000 | Equity Only | 06b | SEC link |
| 2019-02-25 | Amended | $3,970,550 | $2,565,531 | Equity Only | 06b | SEC link |
| 2017-09-20 | Amended | $1,405,019 | $1,405,019 | Equity Only | 06b | SEC link |
| 2016-03-30 | New | Yet to Sell | $0 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Teresa Bair | Director |
| Carlos Camozzi | Executive |
| Susan Elliott | Director, Executive, Promoter |
| Charles Ellis | Director |
| Herve Girsault | Executive |
| Ryan V. Hartwell | Director, Executive, Promoter |
| Mark Miller | Director, Executive, Promoter |
| Joseph Sardano | Director |
| Richard J. Shaw | Executive |
| Jon Verbeck | Executive |
| John Verbeck | Executive |